Trial Profile
Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2024
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 06 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2017 Planned End Date changed from 1 May 2024 to 13 May 2024.